Overcoming PD‑1 Resistance in Relapsed/Refractory Hodgkin Lymphoma
In patients with classic Hodgkin lymphoma that progressed after PD‑1 blockade, a co‑formulated combination of the anti‑LAG3 antibody favezelimab with pembrolizumab restores therapeutic activity compared with investigator‑chosen chemotherapy.
KEYFORM‑008 is a randomized, open‑label, international phase 2 trial that compares the combination of pembrolizumab with the anti‑LAG3 antibody favezelimab to investigator‑chosen chemotherapy in patients with relapsed or refractory classic Hodgkin lymphoma who have progressed after prior PD‑1 inhibition. Early data presented at the 2026 European Hematology Association Congress suggest that dual‑checkpoint inhibition re‑engages exhausted T‑cells and enhances antitumor activity, providing a potential new strategy for patients with PD‑1–resistant disease.
Resistance to PD‑1 inhibitors limits treatment options and survival in relapsed/refractory Hodgkin lymphoma. Targeting the LAG3 axis offers a mechanism to reverse T‑cell exhaustion and restore response to checkpoint therapy, potentially improving outcomes for patients who fail standard PD‑1 blockade.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.
- Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
- Combination of Acimtamig and AlloNK Effective in R/R Classical Hodgkin Lymphoma
- Working towards harmonization of clinical trial reporting in Hodgkin lymphoma
- Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies